$KPTI News

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3

Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move

Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival

Karyopharm Therapeutics To Submit FDA Supplemental New Drug Application In August 2026 For Accelerated Approval Of Selinexor In Combination With Ruxolitinib To Treat Myelofibrosis

Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell

How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis - Slideshow

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026

Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference